External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home AAN 2022
Roche and Genentech at

AAN 2022

April 02 - April 26
Seattle, USA / Virtual (Hybrid)
2022annual
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
05:06 PM
Duration 12mins Ballroom 6B Washington State Convention Center
Long-term efficacy of satralizumab▼ in aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD): Results from the open-label extension periods of SAkuraSky and SAkuraStar
Jeffrey L. Bennett
Neuroscience | Neuromyelitis Optica

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:18 PM
Duration 12mins Ballroom 6B Washington State Convention Center
Long-term safety of satralizumab▼ in neuromyelitis optica spectrum disorder: Results from the open-label extension periods of SAkuraSky and SAkuraStar
Benjamin Greenberg
Neuroscience | Neuromyelitis Optica

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:30 PM
Duration 12mins Ballroom 6B Washington State Convention Center
Treatment Patterns Among Newly Diagnosed Patients with Multiple Sclerosis by Race and Ethnicity
Geiger C, Sheinson D, To TM, Jones D, Bonine N
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 12mins Washington State Convention Center - 605/610
A 104-week delayed-start analysis of PASADENA (Phase II study evaluating the safety and efficacy of prasinezumab in early Parkinson’s disease)
Gennaro Pagano
Neuroscience | Parkinson's Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:54 PM
Duration 12mins Washington State Convention Center in room 607
SUNFISH: 3-year efficacy and safety of risdiplam▼ in Types 2 and 3 SMA
John W Day, Nicolas Deconinck, Elena S Mazzone, Andres Nascimento, Maryam Oskoui, Kayoko Saito, Carole Vuillerot, Giovanni Baranello, Odile Boespflug-Tanguy, Nathalie Goemans, Janbernd Kirschner, Anna Kostera-Pruszczyk, Laurent Servais, Jessica Braid, Marianne Gerber, Ksenija Gorni, Carmen Martin, Renata S Scalco, Wai Yin Yeung, Eugenio Mercuri on behalf of the SUNFISH Working Group
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:18 PM
Duration 12mins Washington State Convention Center in room 607
FIREFISH Parts 1 and 2: 24-month safety and efficacy of risdiplam▼ in Type 1 SMA
John W Day, Odile Boespflug-Tanguy, Basil T Darras, Nicolas Deconinck, Andrea Klein, Riccardo Masson, Maria Mazurkiewicz-Bełdzińska, Eugenio Mercuri, Kristy Rose, Laurent Servais, Dmitry Vlodavets, Hui Xiong, Edmar Zanoteli, Angela Dodman, Muna El-Khairi, Eleni Gaki, Marianne Gerber, Ksenija Gorni, Heidemarie Kletzl, Giovanni Baranello on behalf of the FIREFISH Working Group
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.